All In Biotech

Drug Trial Radar · NCT02431247

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects

Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 725 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

725

Actual

Start

Jul 6, 2015

Primary completion

Mar 2, 2017

Study completion Sep 30, 2020

Sponsor

Lead sponsor
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1 (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.

Conditions

  • Immunodeficiency Virus Type 1, Human

Interventions

  • Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDCDrug

    A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.

  • DRV/COBI FDCDrug

    A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.

  • FTC/TDF FDCDrug

    A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.

  • D/C/F/TAF FDC - Matching PlaceboDrug

    Matching placebo of D/C/F/TAF FDC will be administered once daily.

  • FTC/TDF FDC Matching PlaceboDrug

    Matching placebo of FTC/TDF FDC will be administered once daily.

  • DRV/COBI FDC Matching PlaceboDrug

    Matching placebo of DRV/COBI FDC will be administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot ApproachTime frame: At Week 48

Locations

80 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Bakersfield, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    North Hollywood, California

  • Site not named

    San Francisco, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Ft. Pierce, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Savannah, Georgia

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Berkley, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Hillsborough, New Jersey

  • Site not named

    Newark, New Jersey

  • Site not named

    Somers Point, New Jersey

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    Manhasset, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Antwerp, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Clamart, France

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Lyon, France

  • Site not named

    Marseille, France

  • Site not named

    Montpellier, France

  • Site not named

    Nantes, France

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.